Triple negative breast cancer is the most aggressive subtype of breast cancer and more often affects young women. Patients typically receive chemotherapy, followed by surgery to remove the tumour. This provides the best chance of pathological complete response, meaning no cancerous cells remaining on the resected tumour. KEYNOTE tested whether adding immune therapy to chemotherapy prior to surgery could improve pathological complete response and event-free survival in women with early triple negative breast cancer. A total of 1, patients were randomly allocated at a ratio to pembrolizumab or placebo, both added to preoperative chemotherapy with anthracyclines, taxanes, and platinum, for five to six months.
Patients are typically treated with a combination of surgery, chemotherapy, and radiation. With the exception of advanced and inoperable metastatic breast cancer, breast-conserving surgery BCS , simple mastectomy, or radical mastectomy have remained initial treatments for breast cancer. Although mastectomy to reduce risk of recurrence is preferred over BCS, it is not clear if surgical recommendations should be altered for patients with TNBC. Furthermore, when choosing a surgical approach, the preferences of the patient, as well as clinical and pathologic variables, should be considered. Radiation therapy RT after BCS has shown to be beneficial in the long term for patients with breast cancer. This is thought to be related to more time available for DNA damage repair from radiation in ER-negative cells. Some researchers suggest that RT of the surrounding breast tissue after BCS could eliminate remaining mutated BRCA1 foci and lessen the risk of local or regional recurrence.
When Iraq War correspondent Jennifer Griffin, now 43, was diagnosed with triple-negative breast cancer, she drew on her journalistic strength and skills to get well. The Fox TV reporter sat down with Lifescript to talk about how she survived her biggest battle In fall , Fox newscaster Jennifer Griffin, then 39, was living in the U.